STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRSP
  4. [Form 4] CRISPR Therapeutics AG Insider Trading Activity

CRISPR Therapeutics (CRSP) CEO sells shares to cover RSU taxes

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni reported RSU vesting and a related share sale. On February 18, 2026, he acquired 13,250 Common Shares at $0.00 per share through the exercise/settlement of restricted stock units.

On February 19, 2026, he sold 6,967 Common Shares at an average price of $52.58 per share. A footnote explains that this sale was required to cover tax withholding obligations under the company’s RSU Settlement Policy and was not a discretionary trade. After these transactions, he directly held 226,106 Common Shares.

The restricted stock units were originally granted on February 18, 2022 for 53,000 Common Shares, vesting in four equal annual installments through February 18, 2026.

Positive

  • None.

Negative

  • None.
Insider Kulkarni Samarth
Role Chief Executive Officer
Sold 6,967 shs ($366K)
Type Security Shares Price Value
Sale Common Shares 6,967 $52.58 $366K
Exercise Restricted Stock Units 13,250 $0.00 --
Exercise Common Shares 13,250 $0.00 --
Holdings After Transaction: Common Shares — 226,106 shares (Direct); Restricted Stock Units — 0 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Reflects 85,622 shares previously transferred from the Kulkarni 2023 GRAT to the Reporting Person. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Kulkarni Samarth
(Last) (First) (Middle)
C/O CRISPR THERAPEUTICS
105 WEST FIRST STREET
(Street)
BOSTON MA 02127
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 02/18/2026 M 13,250 A (1) 233,073(2) D
Common Shares 02/19/2026 S 6,967(3) D $52.58 226,106 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 02/18/2026 M 13,250 (4) (4) Common Shares 13,250 (1) 0 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
2. Reflects 85,622 shares previously transferred from the Kulkarni 2023 GRAT to the Reporting Person.
3. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
4. This restricted stock unit award was granted on February 18, 2022 with respect to 53,000 Common Shares, with (i) one quarter of the shares vesting on February 18, 2023, (ii) one quarter of the shares vesting on February 18, 2024, (iii) one quarter of the shares vesting on February 18, 2025, and (iv) one quarter of the shares vesting on February 18, 2026.
/s/ Samarth Kulkarni 02/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did CRISPR Therapeutics (CRSP) report for its CEO?

CRISPR Therapeutics CEO Samarth Kulkarni reported RSU vesting and a related share sale. He exercised restricted stock units into 13,250 Common Shares, then sold 6,967 shares to satisfy tax withholding obligations under the company’s RSU Settlement Policy.

How many CRSP shares did the CEO sell and at what price?

Samarth Kulkarni sold 6,967 CRISPR Therapeutics Common Shares at an average price of $52.58 per share. A filing footnote states the sale was mandated to cover tax withholding from RSU vesting, rather than being a discretionary open-market trade.

Were the CRISPR Therapeutics CEO’s recent share sales discretionary trades?

The Form 4 notes the CEO’s 6,967-share sale was not discretionary. It was required under CRISPR Therapeutics’ RSU Settlement Policy solely to fund tax withholding obligations tied to the vesting of restricted stock units, rather than a voluntary portfolio decision.

How many CRSP shares did the CEO acquire from RSU vesting?

On February 18, 2026, the CEO acquired 13,250 CRISPR Therapeutics Common Shares at $0.00 per share via restricted stock unit settlement. These RSUs were part of a 53,000-share award granted in 2022 that vests in four equal annual installments.

What are the vesting terms of the CEO’s 2022 RSU grant at CRSP?

The 2022 restricted stock unit award for the CEO covers 53,000 CRISPR Therapeutics Common Shares. One quarter vests on each of February 18, 2023, 2024, 2025, and 2026, resulting in staged delivery of shares over four years, subject to continued service.

How many CRISPR Therapeutics shares does the CEO hold after these transactions?

Following the RSU-related acquisition and tax-withholding sale, Samarth Kulkarni directly holds 226,106 CRISPR Therapeutics Common Shares. This balance reflects settlement of 13,250 RSUs into shares and the mandated sale of 6,967 shares to pay associated tax obligations.